NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
NMN (Nicotinamide Mononucleotide) is a substance similar to vitamin B3, which can produce NAD+ (a key metabolic intermediate) in the body. Therefore, studies have shown that NMN may help improve aging-related health issues such as metabolism, immunity, cell repair, brain health, and more.
Currently, NMN supplements are mainly used to treat the following diseases:
Aging-related metabolic disorders such as diabetes, obesity, high cholesterol, etc.
Aging-related neurodegenerative diseases, such as Alzheimer's disease.
Aging-associated immune decline.
Aging-related cardiovascular disease.
NMN supplements are mainly used to increase NAD+ levels to improve metabolic diseases and slow down the aging process.
Improve metabolic diseases: Studies have shown that NMN can improve the symptoms of metabolic diseases such as diabetes, fatty liver and obesity.
Delay the aging process: NMN can increase the vitality of cells, improve the metabolic process of cells, and delay the aging process.
Protect DNA: NAD+ is an important metabolic substance in cells and participates in various biological processes such as cellular energy metabolism and DNA repair. Supplementing NMN can increase NAD+ levels and protect DNA.
Improves Athletic Capacity: NMN has been shown to improve athletic performance and increase fat burning ability
Improve neurodegenerative diseases: Studies have shown that NMN can improve neurodegenerative diseases, such as Alzheimer's disease
However, these studies were small, and NMN has not been shown to be effective in clinical trials, so further research is needed to determine the effectiveness of NMN supplements.
NMN supplements are mainly used to increase NAD+ levels to improve metabolic diseases and slow down the aging process.
Improve metabolic diseases: Studies have shown that NMN can improve the symptoms of metabolic diseases such as diabetes, fatty liver and obesity.
Delay the aging process: NMN can increase the vitality of cells, improve the metabolic process of cells, and delay the aging process.
Protect DNA: NAD+ is an important metabolic substance in cells and participates in various biological processes such as cellular energy metabolism and DNA repair. Supplementing NMN can increase NAD+ levels and protect DNA.
Improves Athletic Capacity: NMN has been shown to improve athletic performance and increase fat burning ability
Improve neurodegenerative diseases: Studies have shown that NMN can improve neurodegenerative diseases, such as Alzheimer's disease
NMN supplements may cause side effects such as upset stomach, diarrhea, and nausea. There is also research showing that NMN supplements may affect insulin sensitivity and insulin levels, so people with diabetes should consult their doctor before taking them.
NMN supplements have not yet undergone large-scale clinical trials to verify their effectiveness. Currently, research on NMN supplements is mainly focused on animal and in vitro experiments. These studies show that NMN can improve the symptoms of metabolic diseases such as diabetes, fatty liver and obesity, and can delay the aging process.
The long-term health effects of NMN supplementation are not well studied. Existing studies mainly focus on animal and in vitro experiments, which show that NMN can improve the symptoms of metabolic diseases such as diabetes, fatty liver and obesity, and can delay the aging process. However, the results of these studies do not represent the long-term effects of NMN on human health.
Introduction Diabetes is one of the dominant causes of death and disability worldwide, greatly affecting the life quality of patients. According to the latest data on diabetes released by the Lancet (GBD Study 2021), type 2 diabetes mellitus (T2DM) cases almost makes up 96.0% of all diabetes cases, with the hallmark of impaired glucose uptake. There are approximately 529 million patients with diabetes in 2021, with age-standardized prevalence of 6.1%. Remarkably, β-nicotinamide mononucleotide (NMN) is able to ameliorate T2DM via unexpected effects on adipose tissue rather than mitochondrial biogenesis. Global age-standardised prevalence of type 1 and type 2 diabetes from 1990 through 2050 forecasts Risk factors for T2DM High body mass index (BMI) is the main risk factor for T2DM, followed by dietary risk factors, environmental or occupational factors, smoking, insufficient physical activity, alcohol consumption, etc. The organ-specific effects of NMN treatment in T2DM NMN alleviates the mildly impaired and energy-inefficient protein synthesis in mice with T2DM induced by high-fat food. Specifically, NMN downregulates spliceosome proteins while upregulating ribosome proteins in hepatocytes. Besides, NMN downregulates proteasome and upregulates DNA replication and cell cycle pathways in muscle cells. Integrated proteomics data analysis of NMN-treated HFD mouse liver. Integrated proteomics data analysis of mouse muscle tissue. Adipose tissue, an energy reservoir, has been attested to be implicated with glucose metabolism. NMN boosts glucose uptake via Resistin downregulation, increased protein synthesis/degradation, fatty acid degradation, lysosome protein upregulation (most notably upregulation of the ATP6V1 proton pump), mTOR cell proliferation signaling in white adipose tissue, differentiation of preadipocytes to brown adipose cells and/or overexpression of thermogenic UCP1, a protein of the inner mitochondrial membrane of brown adipose tissue. Integrated proteomics data analysis of NMN-treated HFD mouse adipose tissue Conclusion NMN exerts organ-specific effects, with a vital role in improving glucose uptake, showing potent potential in the management of metabolic disorders including T2DM. Reference [1] GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203-234. doi:10.1016/S0140-6736(23)01301-6 [2] Popescu RG, Dinischiotu A, Soare T, Vlase E, Marinescu GC. Nicotinamide Mononucleotide (NMN) Works in Type 2 Diabetes through Unexpected Effects in Adipose Tissue, Not by Mitochondrial Biogenesis. Int J Mol Sci. 2024;25(5):2594. Published 2024 Feb 23. doi:10.3390/ijms25052594 BONTAC NMN BONTAC is the pioneer of NMN industry and the first manufacturer to launch NMN mass production, with the first whole-enzyme catalysis technology around the world. At present, BONTAC has become the leading enterprise in niche areas of coenzyme products. Notably, BONTAC is the NMN raw material supplier of famous David Sinclair team at the Harvard University, who uses the raw materials of BONTAC in a paper titled “Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of Vascular Aging”. Our services and products have been highly recognized by global partners. Furthermore, BONTAC has the first national and the only provincial independent coenzyme engineering technology research center in Guangdong, China. The coenzyme products of BOMNTAC are widely used in fields such as nutritional health, biomedicine, medical beauty, daily chemicals and green agriculture. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.
On April 7th, 2023, KPMG China hosted the second Biotech Innovation 50 Enterprises award ceremony online, with CITIC Securities as a co-organizer. Bontac impressed the panel with its strong R&D capabilities and excellent performance in the synthetic biology sector, earning a spot on the "KPMG China 2023 Biotech Innovation Enterprises Top 50" list. The experts panel spent six months selecting the winners based on five core criteria: technology and product leadership, product pipeline richness and original research ratio, core management and R&D team background, capital market activity, and financial health. Bontac shines with its solid strength The "KPMG China 2023 Biotech Innovation Enterprises Top 50" award evaluated the enterprises from various aspects such as products, technology, team, finance, and funding. The selected enterprises are all high-quality enterprises with outstanding abilities in the biotech field, and being on the list is a great recognition. Bontac Deputy (fourth from the left) Bontac, as a leader in the synthetic biology industry, has always been at the forefront of R&D and production of coenzymes such as NMN, NADH and natural products such as ginsenoside Rh2, stevioside RD, etc. It has a strong comprehensive strength and a promising development potential that won the unanimous approval of the experts panel. From a scientific and technological point of view, Bontac has overcome several technical challenges, obtained more than 160 international patents and over 10 honorary qualifications, and owns more than 600 proprietary enzyme libraries. From the perspective of business scale, Bontac has three production bases that can achieve industrial production of hundreds of tons annually. Bontac also serves customers in more than 20 provinces in China and more than 60 countries. With the accordance of team configuration , Bontac has assembled representatives from four sides: scientists, engineers, entrepreneurs, and investors, empowering the enterprise from multiple dimensions. With the continuous upgrade of health consumption, the gradual release of new policy benefits related to medical regulation, and the rapid development of biopharmaceutical technology industry from a high-tech industry with great potential to a high-tech pillar industry. Biotech enterprises with potential represented by Bontac will leverage policy advantages and ride on market opportunities to integrate diverse resources in the ecosystem, support the development of China's biotech innovation enterprises, and enable win-win cooperation for the entire ecosystem. KPMG Biotech Innovation Enterprises Top 50 KPMG Awarding Ceremony KPMG China launched its first "Biotech Innovation Enterprises Top 50" award in 2021 and received widespread attention and support from the industry. KPMG invited distinguished representatives from research, industry, investment, and enterprise fields to share their insights on the hot topics and trends in biotech and explore the best practices for biotech innovation enterprises. The award also created a resource-matching platform for the selected biotech enterprises with potential, helping them seize the policy direction and capital market opportunities, increase their market visibility, and achieve organic growth from within and outside.
Bontac in Boao Health Food Science Conference & Expo(FHE) From 22 to 25 February 2023, the Boao Health Food Science Conference and Expo was successfully held at the permanent venue of the Boao Forum for Asia in Hainan, China. This international conference build an international platform for exchange and cooperation among government, academia, industry, and industry, academia and research, which aims to promote the development of the health food industry through the exchange of scientific information at home and abroad. Bontac performace in FHE The conference gathered several prominent scientists including 10 academicians, over 200 experts and scholars, and invited many popular food enterprises likely Nestle, Pepsi from the United States, Europe, Japan, Australia, New Zealand and other countries. More importantly, exhibition featured a number of high-tech companies that focus on high-tech development of the production of nutritious and healthy food products. As one of the high-tech companies attending the exhibition, Bontac, which has obtained over 160 international patents and is committed to the design of new biosynthetic pathways to explore and mass-produce natural products for food ingredients, was invited to attend the conference and companies vital stake holders to deliver academic views on the technological innovation and healthy development of the food industry. Figure 1: Xinhua Officical Record for Bontac in FHE Bontac Products in FHE Expo Bontac main products starring NMN, rare ginsenosides, NAD, NADH and NADPH were all present at booth C34 in FHE Expo. And that booth C34 attracted lots of exhibitors to consult who communicated with each other upon appearance owing to the obvious striking advantages likely Bontac manufacture technology of whole coenzyme, sustainable supply chain, complete quality system and environment-protection and energy-saving preparation. What’s more, the academician of the Chinese Academy of Engineering and Chairman of FHE, Chen Junshi also visited Bontac booth and highly commend on the Bontac performance and demonstration. Figure 2: Chen Visited Bontac Booth in FHE Bontac recognizes the importance of the upstream of raw material side in biotechnology as the key to product innovation. On the other hand, with the increasingly demand for high-quality food, synthetic biotechnology stands on the point of the potential to provide consumers with greener and healthier food ingredients. Therefore, as far as Bontac is concerned, developing and shaping innovative technology ownership supports to effectively solving the problem of insufficient plant and animal extracts, reducing the environmental burden, and contributing to carbon neutrality and human sustainable development. At present, Bontac has already launched industrialized stevioside and rare ginsenoside which can be utilized in the field of health food. In future, Bontac will set up more product lines for more raw materials with higher purity and better quality as health food ingredients. Bontac honor time in FHE It was great honor for Bontac to win innovative product enterprise award, which identified Bontac long-term commitment to the exploration and innovation of synthetic biology and health technology products. Furthermore, it also reflects the R&D capability and innovation ability of Bontac in the field of synthetic biology, which will surely inspire Bontac to invest more actively in R&D and innovation. Figure 3: Bontac Award in FHE Dr. Qi Zhang, Founder and Chief Scientist of Bontac, delivered a speech entitled Efficient Green Biosynthesis of Ginsenosides, NMN and other Natural Products at the Innovative Technology and Innovative Manufacturing forum, explaining the green safety, wide applicability and innovative value of synthetic biotechnology from the theoretical source. Figure 4: Dr. Zhang in FHE Dr. Zhang demonstrated that Bontac holds up on the technology of biosynthesis of coenzyme preparation for natural products such as ginsenosides, especially rare ginsenosides Rh2 and Rg3. The advantages focuses on breaking through the limitations of raw materials, facilitating industrial scale-up, shorting reaction cycle, milder conditions, green environment and energy saving, but maintains the point of sustainable development. On the 23rd, a roundtable discussion on the "Technology and Investment in the Food Industry". Shu Shangke, Chairman of Bontac, attended the forum on the theme of Technology and Investment in the Food Industry and said that synthetic biotechnology is bringing about a revolution in the food and pharmaceutical fields, pushing these fields to iterate and upgrade. In the food industry, having strong R&D strength, leading technology and abundant patents are important factors for a company to have core competitiveness and investment value. Figure 5: Shu in FHE